Historical record - last NADAC effective date: 8/23/2023
Product Information
SUMATRIPTAN-NAPROXEN 85-500 MG is a generic product labeled by Currax Pharmaceuticals LLC, priced at $17.8743 per EA under NDC 44183085009. Its NADAC has been published 272 times since Jul 18, 2018.
FDA first approved this application on Apr 15, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
500; 85 mg/1; mg/1
Manufacturer
Currax Pharmaceuticals LLCNDC
44183085009
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
8/23/2023
Active Ingredients
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA021926FDA Approved
4/15/2008
TE Code
AB
On Market Since
5/14/2015
Pharmacological Classes
Price Statistics
The NADAC for SUMATRIPTAN-NAPROXEN 85-500 MG has been published 272 times since Jul 18, 2018, and over the history we have for it it has declined 63.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $17.8743 per EA |
|---|---|
| All-time high | $64.2190 (Nov 14, 2018) |
| All-time low | $14.7549 (Jan 18, 2023) |
| Median price | $32.2535 |
| Average price | $34.3990 |
| Largest weekly change | +47.6% (May 18, 2022) |
| Weeks tracked | 272 |
| Tracking since | Jul 18, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
-16.4%
All
-63.2%
Last surveyed Sep 27, 2023 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the sumatriptan succinate and naproxen sodium market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Currax Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
sumatriptan succinate and naproxen sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SUMATRIPTAN-NAPROXEN 85-500 MG?
The current National Average Drug Acquisition Cost (NADAC) for SUMATRIPTAN-NAPROXEN 85-500 MG, manufactured by Currax Pharmaceuticals LLC, is $17.8743 per EA (NDC 44183085009), effective Sep 27, 2023.
How has the price of SUMATRIPTAN-NAPROXEN 85-500 MG changed over time?
Over the history we have for it, the NADAC for SUMATRIPTAN-NAPROXEN 85-500 MG has declined 63.2%. It has been tracked across 272 weekly CMS publications since Jul 18, 2018.
What are the highest and lowest recorded NADAC prices for SUMATRIPTAN-NAPROXEN 85-500 MG?
Since Jul 18, 2018, the NADAC for SUMATRIPTAN-NAPROXEN 85-500 MG has ranged from a low of $14.7549 (Jan 18, 2023) to a high of $64.2190 (Nov 14, 2018), with a median of $32.2535 per EA.
Are there cheaper alternatives to SUMATRIPTAN-NAPROXEN 85-500 MG?
No other NADAC-published product currently shares the active ingredient and strength of SUMATRIPTAN-NAPROXEN 85-500 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SUMATRIPTAN-NAPROXEN 85-500 MG?
SUMATRIPTAN-NAPROXEN 85-500 MG (NDC 44183085009) is labeled by Currax Pharmaceuticals LLC, and CMS classifies it as a generic product.